Cosmos Health Partners with Prime Ledger to Manage $300M Treasury and Tokenize IP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: Newsfilter
- Strategic Partnership: Cosmos Health has entered a long-term strategic partnership with Prime Ledger to digitally transform its financial operations, particularly managing a $300 million treasury, thereby enhancing efficiency and reducing risk in treasury management.
- Asset Tokenization: A cornerstone of this collaboration is the tokenization of Cosmos Health's high-value intellectual property, with Prime Ledger designing a token issuance platform that will unlock new capitalization channels and drive innovation and growth.
- Data Infrastructure Integration: The partnership also includes integrating Cosmos Health's data infrastructure using Prime Ledger's relationship with Conduit Network, which will optimize on-chain and off-chain data management, enhancing financial reporting and compliance capabilities.
- Project Commencement: The initial phase of this engagement is set to begin in Q4 2025, focusing on strategic planning and platform design, marking a significant advancement for Cosmos Health in the digital economy.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
YYAI Director Hongyu Zhou Acquires 4.215M Shares at $1.37, Totaling $5.77M
- YYAI Large Transaction: Director Hongyu Zhou purchased 4.215 million shares of YYAI on Wednesday at $1.37 each, totaling an investment of $5.77 million, reflecting confidence in the company's future and contributing to a 15% increase in stock price on Friday.
- Investment History: Over the past twelve months, Zhou has made three purchases of YYAI shares, totaling $1.86 million at an average cost of $1.29 per share, indicating a sustained positive outlook on the company.
- Cosmos Health Insider Trading: CEO Grigorios Siokas bought 353,321 shares of COSM on Tuesday at $0.50 each, totaling $175,000, which reflects recognition of the company's value, even as the stock rose only 0.7% on Friday.
- Siokas' Investment History: Siokas has made 26 purchases of COSM shares over the past year, totaling $1.93 million at an average cost of $0.45 per share, demonstrating confidence in the company's long-term growth potential.
Continue Reading
Cosmos Health Inc. (COSM) Receives Zacks Coverage with $4.50 Price Target
- Coverage Initiation: Zacks Small-Cap Research initiated coverage on Cosmos Health on January 13, 2026, assigning a $4.50 per share valuation, reflecting the company's diversified revenue base and improving financial performance.
- Revenue Growth Outlook: Zacks projects Cosmos Health's revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with expectations of exceeding $130 million by 2027, driven by higher-margin pharmaceuticals and nutraceuticals.
- U.S. Market Expansion: The report highlights Cosmos Health's entry into the U.S. market through the acquisition of ZipDoctor, a telehealth platform, and the launch of Sky Premium Life in the U.S. nutraceutical market, enhancing its competitive position.
- Advancing R&D Pipeline: Zacks notes Cosmos Health's ongoing development programs targeting obesity and multiple sclerosis, reflecting the company's strategic focus on addressing large disease markets and driving innovation in drug repurposing.
Continue Reading